# Vbiosci

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vbiosci

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.vbiosci.com
- Total disclosed funding: $31M
- Latest round: Series B (Jun 21, 2023)
- Investors on record: 14

## About

Established in 2016 and based in Beijing, China, Beijing Dingchi Biotechnology Co., Ltd., traing as Vbiosci, is an animal vaccine company that focuses on cell growth technology and biological new drug development. The founder and chairman of the company, Ningning Ma graduated from Ohio State University and has worked in Sino Biological Inc. and Pfizer Inc. The founding team has experience in immunology and animal vaccine development. In April 2026, Vbiosci raised a venture funding from Efung Capital.

The company developed a research and development platform technology system from genes to antibody products in the field of animal vaccines that includes new vaccine technology research platform, antibody-drug research platform, and pilot-scale expression platform. Specific products and services include vaccine development, new drug development, and large-scale suspension cell growth technology. It has developed ST, PK-15, Vero and other cells, as well as CHO cell antibody production technology. The pipeline under development includes three sectors, which are poultry, livestock, and pets. Vbiosci also provides products such as cat food and freeze-dried fresh meat pellets.

The company generates revenue by providing animal vaccines, pet medicines, and pet products.

The financing raised in March 2026 is a testament to the capital market's strong recognition of Vbiosci's technological strength, product pipeline, and development prospects, and will inject strong momentum into the company's subsequent R&D innovation, capacity expansion, and market development.

## Funding rounds

- Series B, Jun 21, 2023 — Huagai Capital
- Series B, Sep 26, 2022 — Oriental Fortune Capital, 3E Bioventures Capital, Yijing Investment, Zheke Investment Management, Suzhou Trust, Zhaoken Capital Management (Beijing)
- Series A, Sep 18, 2021, $31M — Sinowisdom, CMB International Asset Management, Topping Capital
- Series A, Dec 11, 2020 — CMB International Asset Management, E-Town International Industrial Investment, Jinkong Capital, Tongxieyi Ventures, Topping Capital, Chenchuang Lihe

## Investors

- CMB International Asset Management (https://capitalatlas.ai/funds/cmb-international-asset-management) — Series A
- E-Town International Industrial Investment (https://capitalatlas.ai/funds/e-town-international-industrial-investment) — Series A
- Jinkong Capital (https://capitalatlas.ai/funds/jinkong-capital) — Series A
- Tongxieyi Ventures — Series A
- Topping Capital (https://capitalatlas.ai/funds/topping-capital) — Series A
- Chenchuang Lihe — Series A
- Sinowisdom (https://capitalatlas.ai/funds/sinowisdom) — Series A
- Oriental Fortune Capital (https://capitalatlas.ai/funds/oriental-fortune-capital) — Series B
- 3E Bioventures Capital (https://capitalatlas.ai/funds/3e-bioventures-capital) — Series B
- Yijing Investment (https://capitalatlas.ai/funds/yijing-investment) — Series B
- Zheke Investment Management (https://capitalatlas.ai/funds/zheke-investment-management) — Series B
- Suzhou Trust — Series B
- Zhaoken Capital Management (Beijing) (https://capitalatlas.ai/funds/zhaoken-capital-management-beijing) — Series B
- Huagai Capital (https://capitalatlas.ai/funds/huagai-capital) — Series B